Drug Profile
Research programme: caspase inhibitors - Texas Biotechnology
Alternative Names: Caspase inhibitors research programme - Texas BiotechnologyLatest Information Update: 24 Apr 2007
Price :
$50
*
At a glance
- Originator Encysive Pharmaceuticals
- Class
- Mechanism of Action Caspase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Myocardial infarction; Stroke
Most Recent Events
- 24 Apr 2007 Discontinued - Preclinical for Myocardial infarction in USA (unspecified route)
- 24 Apr 2007 Discontinued - Preclinical for Stroke in USA (unspecified route)
- 21 Nov 2001 Preclinical development for Myocardial infarction in USA (Unknown route)